Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies to Merge
Date:5/28/2008

ccessfully execute their integration strategies, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities, risks that the combined company will not be able to maintain listing on NASDAQ, as well as other risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. A more complete discussion of risks and uncertainties that may affect forward-looking statements is included in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007, and its Quarterly Report on Form 10-Q for the first quarter of 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Sonus. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Proxy Solicitation

In connection with the proposed merger, Sonus intends to file with the SEC a Proxy Statement and related materials and to mail to its stockholders the final Proxy Statement containing information about Sonus, OncoGenex and the proposed merger. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SONUS, ONCOGENEX AND THE PROPOSED MERGER.

Sonus and OncoGenex, and certain of their directors, executive officers and other members of management and employees may be deemed to be participants in
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
2. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
3. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
4. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
5. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
6. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
7. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... 19, 2014 A Geisinger researcher on a ... a Centers for Disease Control and Prevention (CDC) award ... health concern. Joseph Boscarino , Ph.D. ... a team of researchers nominated for the Centers for ... Award for Data Methods and Study Design. ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... Oxide Fuel Cells (SOFCs) - Global Strategic Business Report" ... the worldwide markets for Solid Oxide Fuel Cells (SOFCs) in ... US, Canada , Europe ... Annual estimates and forecasts are provided for the period 2012 ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... International Daleco Corporation (Pink Sheets: ILDO) announces its ... joint venture company, ICAP Bio Organic, S. de R.L. ... and proprietary bio-organic catalyst compositions (BOCs) within Central America, Mexico ... renewable energy credit opportunities where available. , SIF ICAP ...
... , BEIJING, Oct. 27 /PRNewswire-Asia/ ... provider of biopharmaceutical products in China, announced today that,it ... vaccine, PANFLU.1, from,China,s Ministry of Industry and Information Technology ... is required to produce an,additional 5.19 million doses of ...
... YORK, Oct. 26 Reportlinker.com announces ... is available in its catalogue. , ... Pipeline Analysis and Competitive Assessment ... , In the nearly 35 ...
Cached Biology Technology:Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean. 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 2Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 4Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 5Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 6Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 7Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 8
(Date:8/20/2014)... of the Para and Mato Grosso states of Brazil. ... in order to deforest the land. Deforestation is the ... the land is thereafter converted to a nonforest use. ... ranches, or urban use. The herringbone-patterned tan lines cutting ... the middle of the image are evidence of deforestation ...
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... The Wildlife Conservation Society has launched an ambitious new program ... in key areas over the next decade, according to an ... called "Tigers Forever," blends a business model with hard science, ... have pledged an initial $10 million to support it. , ...
... has developed a remarkable nanostructured material that can repel pests ... used as a timed drug delivery system –as a nasal ... Washington University James S. McDonnell Distinguished University Professor in Arts ... developed more than four years ago as marine "antifouling" coatings ...
... study shows that statins, which are typically used as ... C virus (HCV). They could replace ribavirin in combination ... July 2006 issue of Hepatology, the official journal of ... (AASLD). Published by John Wiley & Sons, Inc., Hepatology ...
Cached Biology News:Tigers get a business plan 2Triple threat polymer captures and releases 2Triple threat polymer captures and releases 3Triple threat polymer captures and releases 4Statins stop hepatitis C virus from replicating 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
versican (H-56)...
... presents PsiPort Mass Directed Auto Purification ... data acquisition system designed for automated ... life science and pharmaceutical discovery programs. ... to simplify high throughput mass directed ...
Biology Products: